5-Amino-1MQ (5-Amino-1-methylquinolinium)

5-Amino-1MQ is technically a small molecule rather than a peptide, but it's sold by peptide suppliers and prescribed by peptide clinicians, so it ends up in the peptide therapy conversation. It's an inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme that's emerged as a target for metabolic health and obesity treatment. The target itself is well-validated. Kraus et al. published in Nature (PMID: 24670636) that NNMT knockdown in mice increased energy expenditure and reduced fat mass, establishing the enzyme as a legitimate therapeutic target. NNMT is overexpressed in white adipose tissue of obese individuals, and it catalyzes a reaction that has two problematic consequences: it drains NAD+ precursors (by methylating nicotinamide) and it consumes methyl donors (SAM, S-adenosylmethionine). Both effects shift cellular metabolism toward fat storage and away from fat oxidation. Neelakantan et al. (PMID: 29355482) tested 5-Amino-1MQ specifically and showed that treating diet-induced obese mice with the compound for 11 days reduced body weight, fat mass, and adipocyte size. The interesting finding was that the mice didn't eat less. They lost fat because their metabolic rate increased, not because their appetite decreased. This is a mechanistically different approach from GLP-1 agonists (which reduce appetite) or amphetamine-like drugs (which stimulate the CNS). The NAD+ connection is worth understanding. NAD+ is a cofactor required by hundreds of metabolic enzymes, including the sirtuins (SIRT1-7) that regulate mitochondrial function, DNA repair, and aging-related pathways. NAD+ levels decline with age, and restoring them is the rationale behind NMN and nicotinamide riboside (NR) supplementation. NNMT inhibition preserves NAD+ through a different mechanism: instead of providing more NAD+ precursors (the NMN/NR approach), it prevents their wasteful methylation by NNMT. The two approaches are potentially synergistic. The evidence limitation is straightforward: no human clinical trial data has been published for 5-Amino-1MQ. Everything we know comes from animal studies and in vitro experiments. The clinical use is based on extrapolation from animal dosing and anecdotal reports from prescribing clinicians and patients. This is a common situation in the peptide therapy space, but it means we're operating with less certainty about optimal dosing, true efficacy magnitude, and long-term safety. Typical protocols use 50-150 mg daily, taken orally. The oral bioavailability is an advantage over most peptides, which require injection. Some practitioners cycle the compound (4-8 weeks on, 2-4 weeks off) to avoid potential adaptation, though there's no published data supporting a specific cycling protocol. Side effects reported anecdotally include mild GI discomfort and headache. The theoretical concern with chronic NNMT inhibition is whether long-term enzyme blockade could have unintended consequences on methylation pathways or nicotinamide metabolism that haven't been studied in multi-month or multi-year timeframes. Cost runs $100-250/month from compounding pharmacies, positioning it as a mid-range metabolic optimization compound. For individuals considering 5-Amino-1MQ, the honest assessment is: strong target validation, good animal data, zero human clinical trial data. It's a rational bet on a well-characterized mechanism, but it's still a bet.